XML 80 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Major Customers and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2013
Risks and Uncertainties [Abstract]  
Major Customers and Concentration of Credit Risk
Major Customers and Concentration of Credit Risk
 
Customer
2013
 
% of Total
Revenue
 
2012
 
% of Total
Revenue
 
2011
 
% of Total
Revenue
Roche
$
9,181,759

 
68
%
 
$
—

 
—
%
 
$
—

 
—
%
NIAID
2,090,939

 
16

 
2,831,115

 
69
%
 
7,801,976

 
80
%
VGX Int'l (affiliated entity)
425,000

 
3

 
577,467

 
14

 
411,459

 
4

All other
1,769,648

 
13

 
710,070

 
17

 
1,581,822

 
16

Total Revenue
$
13,467,346

 
100
%
 
$
4,118,652

 
100
%
 
$
9,795,257

 
100
%

During the years ended December 31, 2013, 2012 and 2011, the Company recognized revenue from various license fees and milestone payments, collaborative research and development agreements, grants and government contracts. As of December 31, 2013, $2.6 million or 79% and $382,000 or 12% of accounts receivable was attributed to Roche and the NIAID, respectively. As of December 31, 2012, $612,000 or 71% and $95,000 or 11% of accounts receivable was attributed to the NIAID and University of Pennsylvania, respectively.
There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.